Literature DB >> 10828627

Cutaneous monomorphous CD4- and CD56-positive large-cell lymphoma.

T Nagatani1, H Okazawa, T Kambara, K Satoh, H Tokura, M Miyazawa, R Yamada, N Baba, H Nakajima, E Yamazaki, H Kanamori, H Mohri.   

Abstract

BACKGROUND: Recently, CD56 (NCAM)-positive lymphomas, such as nasal and nasal-type angiocentric NK/T cell lymphoma, aggressive NK cell leukemia/lymphoma and blastic NK cell lymphoma, were described by several authors as a unique group of lymphoma.
OBJECTIVE: In this study, we intend to clarify the clinicopathological features of cutaneous CD4+ and CD56+ lymphoma.
METHODS: Four patients with cutaneous CD4+ and CD56+ lymphoma were studied.
RESULTS: Age at the first examination ranged from 71 to 89 years (mean = 81.2 years). One patient was female and 3 were males. The organ mainly involved at presentation was the skin. Lymphadenopathy, splenomegaly, leukemic spread and central nervous system involvement were observed as the disease progressed. The mean survival time was 12.2 months. Epstein-Barr virus was not detected within the tumor cells.
CONCLUSION: This peculiar lymphoma is different from nasal and nasal-type angiocentric NK/T cell lymphoma and aggressive NK cell leukemia/lymphoma. Similar cases have been reported as blastic NK cell lymphoma/leukemia. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828627     DOI: 10.1159/000018383

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  2 in total

1.  Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two cases.

Authors:  Nóra Eros; Márta Marschalkó; Katalin Balassa; Bernadett Hídvégi; József Szakonyi; Sándor Ilniczky; Katalin Borka; Attila Kovács; Gyula Bottlik; Judit Hársing; Judit Csomor; Agota Szepesi; András Matolcsy; Sarolta Kárpáti; Judit Demeter
Journal:  J Neurooncol       Date:  2009-10-02       Impact factor: 4.130

Review 2.  What is CD4+CD56+ malignancy and how should it be treated?

Authors:  P Reimer; T Rüdiger; D Kraemer; V Kunzmann; F Weissinger; A Zettl; H Konrad Müller-Hermelink; M Wilhelm
Journal:  Bone Marrow Transplant       Date:  2003-10       Impact factor: 5.483

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.